Guideline on safety and efficacy follow-up and risk management of advanced therapy medicinal products

Current effective version

PDF iconAdopted guideline

Currently under revision - see below

Reference numberEMEA/149995/2008
Effective from31/12/2008

Guideline on safety and efficacy, follow-up - risk management of advanced therapy medicinal products (ATMPs)

DescriptionThe guideline describes specific aspects of pharmacovigilance, risk management planning, safety and efficacy follow-up of authorised ATMPs, as well as some aspects of clinical follow-up of patients treated with such products.

Document history

Revision 1

In progess

PDF iconDraft guideline

Published: 01/02/2018

Deadline for comments: 30/04/2018

First version

Current version

PDF iconAdopted guideline In operation: 31/12/2008–present

How useful was this page?

Add your rating
1 rating